SHIEF SHIELD THERAPEUTICS PLC

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. The company's lead product is Ferric Maltol, marketed in the European Union as Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anaemia in adults. It also develops PT20, a novel therapy that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease; PT30 to treat hypo-allergenic IV iron therapy; and PT40, the first generic version of iron sucrose. The company was founded in 2008 and is based in Gateshead, the United Kingdom.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$0.09    OTCQX
As of 07/01/2022     OTCMarkets


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Unknown
Industry:  
Index country:  United Kingdom
Country of incorporation:  
IPO date:  12/24/2019
Outstanding shares:  216,192,462
Average volume:  1,588
Market cap:   $20,062,660
Current dividend yield:  0.00%
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy